Allan Didriksen, Jette Jakobsen, Rolf Jorde, Vitamin D Stored in Fat Tissue During a 5-Year Intervention Affects Serum 25-Hydroxyvitamin D Levels the Following Year, The Journal of Clinical Endocrinology & Metabolism, Volume 102, Issue 10, 1 October 2017, Pages 3731–3738, https://doi.org/10.1210/jc.2017-01187.
Janmohamed A., Trivedi P. J. Patterns of disease progression and incidence of complications in primary biliary cholangitis (PBC). Best Pract Res Clin Gastroenterol 2018;34–35:71-83.
John K. Olynyk, Bruce A. Luxon, Robert S. Britton, Bruce R. Bacon. Hepatic iron concentration in hereditary hemochromatosis does not saturate or accurately predict phlebotomy requirements The American Journal of Gastroenterology Volume 93, Issue 3, March 1998, Pages 346–350 DOI: 10.1111/j.1572–0241.1998.00346.x
Jorde R., Sollid S. T., Svartberg J., Schirmer H., Joakimsen R. M., Njоlstad I., Fuskevåg O. M., Figenschau Y., Hutchinson M. Y. Vitamin D 20,000 IU per Week for Five Years Does Not Prevent Progression From Prediabetes to Diabetes. J Clin Endocrinol Metab. 2016 Apr;101(4):1647-55. doi: 10.1210/jc.2015–4013. Epub 2016 Feb 1. PMID: 26829443.
Karl-Heinz Wagner, Ryan G. Shiels, Claudia Anna Lang, Nazlisadat Seyed Khoei & Andrew C. Bulmer (2018) Diagnostic criteria and contributors to Gilbert’s syndrome, Critical Reviews in Clinical Laboratory Sciences, 55:2, 129–139.
Kotlyar D. S. et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):36.
Kratzer W. et al. Factors affecting liver size: a sonographic survey of 2080 subjects. J Ultrasound Med. 2003;22(11):1155.
L. D’Antiga, U. Beuers, G. Ronzitti et al. Gene Therapy in Patients with the Crigler – Najjar Syndrome / N Engl J Med 2023; 389:620–631.
L. Peters, S. Burkert, B. Grüner Parasites of the liver – epidemiology, diagnosis and clinical management in the European context / Journal of Hepatology 2021 vol. 75 j 202–218 DOI: https://doi.org/10.1016/j.jhep.2021.02.015.
Lee Y. M., Kaplan M. M. Primary sclerosing cholangitis. N Engl J Med. 1995;332(14):924.
LiverTox: Clinical and Research Information on DrugInduced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Androgenic Steroids. [Updated 2020 May 30].
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury.
M. Pompili, F. Ardito, E. Brunetti et al. Benign liver lesions 2022: Guideline for clinical practice of AISF, SIRM, SIC, SIUMB, AICEP, SITO, SIAPEC–IAP – Part I – Cystic lesions Digestive and Liver Disease 54 (2022) 1469–1478.
Margolskee E. et al. Hepatocellular adenoma classification: a comparative evaluation of immunohistochemistry and targeted mutational analysis. Diagn Pathol. 2016;11:27.
Mitchell M. C. et al. Budd-Chiari syndrome: etiology, diagnosis and management. Medicine (Baltimore). 1982;61(4):199.
Nagy N. E., Holven K. B., Roos N., Senoo H., Kojima N., Norum K. R., Blomhoff R. 1997. Storage of vitamin A in extrahepatic stellate cells in normal rats. J Lip Res 38: 645–658.
Nguyen B. N. et al. Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol. 1999;23(12):1441.
Nima Niknejad, Duncan Fox, Jennifer L. Burwinkel et al. ASO silencing of a glycosyltransferase, Poglut1, improves the liver phenotypes in mouse models of Alagille syndrome. Hepatology ():10.1097/HEP.0000000000000380, April 7, 2023.
Nouel O. et al. Fulminant hepatic failure due to transient circulatory failure in patients with chronic heart disease. Dig Dis Sci. 1980;25(1):49.
Novotny L., Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood) 2003; 228:568–571.
Osler W. The evolution of modern medicine. New Haven, USA: Yale University Press; 1921. pp. 20–26.
Park M. A. et al. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore). 2003;82(5):291.
Plessier A., Valla D. C. Budd-Chiari syndrome. Semin Liver Dis. 2008 Aug;28(3):259–69.
Prikhodko V. A.; Bezborodkina N. N.; Okovityi S. V. Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates. Biomedicines 2022, 10, 274. https://doi.org/10.3390/ biomedicines10020274.
Rautou P. E. et al. Pregnancy: a risk factor for Budd-Chiari syndrome? Gut 2009;58:606–608.
Reuben A. The body has a liver. Hepatology. 2004;39:1179–1181.
Shakespeare W. The Merchant of Venice. London: The Arden Shakespeare; 2001.
Shan L., Wang F., Zhai D., Meng X., Liu J., Lv X. New Drugs for Hepatic Fibrosis. Front Pharmacol. 2022 Jun 13;13:874408. doi: 10.3389/fphar.2022.874408. PMID: 35770089; PMCID: PMC9234287.
Steindl P. et al. Wilson’s disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology. 1997;113(1):212.
T. Reiberger, S. Lens, G.Cabibbo et al. EASL position paper on clinical follow-up after HCV cure / Journal of Hepatology, August 2024. vol. 81 j 326–344. DOI: https://doi.org/10.1016/j.jhep.2024.04.007.
Thuluvath P. J. et al. Acute liver failure in Budd-Chiari syndrome and a model to predict mortality. Hepatology international, 2020;15(1), 146–154.
Tiniakos D. G., Kandilis A., Geller S. A. Tityus: a forgotten myth of liver regeneration. J Hepatol. 2010;53:357–361.
Tiniakos D. G., Kandilis A., Geller S. A. Tityus: a forgotten myth of liver regeneration. J Hepatol. 2010;53:357–361.
Trivedi P. J. et al. Epidemiology, Natural History, and Outcomes of Primary Sclerosing Cholangitis: A Systematic Review of Population-based Studies. Clin Gastroenterol Hepatol. 2022;20(8):1687. Epub 2021 Aug 30.
Valastro Canale A. Etimologie o origini. Torino: UTET; 2004. Isidoro di Siviglia.
Yabe M. et al. Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors. Hum Pathol. 2018;74:5.
Безбородкина Н. Н., Оковитый С. В., Кудрявцев Б. Н. Углеводный метаболизм при хронических поражениях печени. СПб.: Синтез Бук, 2008. 176 с.: ил.
Гепатопротекторы: руководство для врачей / С. В. Оковитый, В. А. Приходько, Н. Н. Безбородкина, Б. Н. Кудрявцев. 2-е изд., перераб. и доп. Москва: ГЭОТАР-Медиа, 2022. 240 с.: ил. DOI: 10.33029/ 9704– 6689-6-LIV-1-240.
Райхельсон К. Л., Маевская М. В., Жаркова М. С., Гречишникова В. Р., Оковитый С. В., Деева Т. А., Марченко Н. В., Прашнова М. К., Ивашкин В. Т. Жировая болезнь печени: новая номенклатура и ее адаптация в Российской Федерации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024. https://doi.org/10.22416/1382-4376-2024-961.
Примечания
1
Имеющие в своем составе расположенные с разных сторон участки или области с противоположными – гидрофильными и гидрофобными – свойствами.
